Delayed seizure associated with paclitaxel-Cremophor EL in a patient with early-stage breast cancer

Pharmacotherapy

Volumn 29, Issue 8, 2009, Pages 993-996

  O'Connor, Tracey L ^a   Kossoff, Ellen ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Adjuvant chemotherapy; Breast cancer; Cremophor EL; Delayed seizure; Emulsifying agent; Neurotoxicity; Paclitaxel; Tonic clonic seizure

Indexed keywords

CREMOPHOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DICHLORALPHENAZONE; DIPHENHYDRAMINE; DOXORUBICIN; FAMOTIDINE; ISOMETHEPTENE MUCATE; OMEPRAZOLE; PACLITAXEL; PARACETAMOL; PHENYTOIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ANAMNESIS; ARTICLE; BRAIN RADIOGRAPHY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; DISEASE ACTIVITY; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; MASTECTOMY; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; RATING SCALE; SCORING SYSTEM; SEIZURE; TONIC CLONIC SEIZURE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; FEMALE; GLYCEROL; HUMANS; PACLITAXEL; PHARMACEUTICAL VEHICLES; SEIZURES; TIME FACTORS;

EID: 68149160023     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.8.993     Document Type: Article

References (15)

1. Bedford Laboratories. Paclitaxel injection package insert. Bedford, OH; 2006. Available from www.bedfordlabs.com/products/inserts/PTXP05.pdf.
2. Scripture C, Figg W, Sparreboom A. Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. Ther Clin Risk Manag 2005;1(2):107-114
3. Cronk M, Abrahm R, Perrin L. Case report of a generalized seizure related to paclitaxel. J Natl Cancer Inst 2004;96(6):48. (Pubitemid 38443653)
4. McGuire W, Rowinsky E, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-279 (Pubitemid 19204753)
5. Rowinsky E, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993;20(4 suppl 3):1-15. (Pubitemid 23239390)
6. Perry JR, Warner E. Transient encephalopathy after paclitaxel (Taxol) infusion. Neurology 1996;46 (6):1596-1599 (Pubitemid 26185778)
7. Rowinsky EK, Burke PJ, Karp JE, et al. Phase I study of Taxol in refractory adult acute leukemia. Cancer Res 1989;49:4640-4647
8. van Zuylen L, Gianni L, Verweij J, et al. Inter-relationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients. Anticancer Drugs 2000;11:331-337 (Pubitemid 30459468)
9. Briasoulis E, Karavasilis V, Tzamakou E, et al. Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study. Anticancer Drugs 2002;13:481-489 (Pubitemid 34621052)
10. Habazettl H, Volmar B, Rohrich F, Conzen P, Doenicke A, Baethmann A. Anesthesiologic efficacy of propanidid as a liposome dispersion: an experimental study in rats. Anaesthesist 1992;41:448-456
11. Boer HH, Moore van Delft CM, Muller LJ, Kiburg B, Vermorken JB, Heimans JJ. Ultrastructural neuropathological effects of Taxol on neurons of the freshwater snail Lymnaea stagnalis. J Neurooncol 1995;25:49-57.
12. Windebank AJ, Blexrud MD, de-Groen PC. Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther 1994;268:1051-1056
13. Setkowicz Z, Guzik R. Injections of vehicle, but not cyclosporin A or tacrolimus (FK506), afford neuroprotection following injury in the developing rat brain. Acta Neurobiol Exp 2007;67:399-409.
14. Naranjo C, Busto U, Sellers E, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-245
15. Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-1598 (Pubitemid 32778603)